ATE437185T1 - Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon - Google Patents

Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon

Info

Publication number
ATE437185T1
ATE437185T1 AT06711342T AT06711342T ATE437185T1 AT E437185 T1 ATE437185 T1 AT E437185T1 AT 06711342 T AT06711342 T AT 06711342T AT 06711342 T AT06711342 T AT 06711342T AT E437185 T1 ATE437185 T1 AT E437185T1
Authority
AT
Austria
Prior art keywords
mutant
applications
single chain
directed against
chain antibodies
Prior art date
Application number
AT06711342T
Other languages
English (en)
Inventor
Beka Solomon
Sara Orgad
Itai Benhar
Ronit Rosenfeld
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE437185T1 publication Critical patent/ATE437185T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06711342T 2005-03-25 2006-03-23 Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon ATE437185T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66496705P 2005-03-25 2005-03-25
US69891905P 2005-07-14 2005-07-14
PCT/IL2006/000372 WO2006100681A2 (en) 2005-03-25 2006-03-23 Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses

Publications (1)

Publication Number Publication Date
ATE437185T1 true ATE437185T1 (de) 2009-08-15

Family

ID=36617330

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06711342T ATE437185T1 (de) 2005-03-25 2006-03-23 Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon

Country Status (6)

Country Link
US (2) US8039594B2 (de)
EP (1) EP1863846B1 (de)
JP (1) JP2008533986A (de)
AT (1) ATE437185T1 (de)
DE (1) DE602006007967D1 (de)
WO (1) WO2006100681A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437185T1 (de) 2005-03-25 2009-08-15 Univ Ramot Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
WO2008011503A2 (en) * 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
WO2008093331A1 (en) * 2007-01-29 2008-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antibody conjugates for circumventing multi-drug resistance
WO2009063461A1 (en) * 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
IL208820A0 (en) * 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
EP2573565A1 (de) 2011-09-23 2013-03-27 Gerhard Matthias Kresbach Immunnachweisverfahren für gemeinsame Epitope von zwei oder mehr Analyten in Proben mit komplexen Zusammensetzungen, Vorrichtung und Kit zum Ermöglichen dieses Immunnachweisverfahrens
CA2980292A1 (en) * 2015-03-23 2016-09-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
BR112017027246A2 (pt) 2015-06-19 2018-08-28 Miyamoto Etsuko marcador de indução de degradação de proteína e uso do mesmo
GB201617564D0 (en) * 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
EP3542821A4 (de) * 2016-11-15 2020-05-27 Tokyo University of Science Foundation P53-abbauinduzierendes molekül und pharmazeutische zusammensetzung
CN110035775A (zh) 2016-11-15 2019-07-19 学校法人东京理科大学 Ras蛋白分解诱导分子和药物组合物
WO2018213467A1 (en) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
WO2023060115A1 (en) * 2021-10-05 2023-04-13 The Penn State Research Foundation Methods for treating cancers with mutated p53
KR20250035548A (ko) * 2022-07-10 2025-03-12 엠브레이스 테라퓨틱스, 인크. 재조합 항체 생산의 무세포 방법
CN115876993B (zh) * 2022-11-17 2024-10-15 沈阳农业大学 基于生物膜干涉技术检测病原生物凝集素与唾液酸乳糖亲和力方法的建立

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2755144B1 (fr) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa Fragments d'anticorps a chaine unique anti-p53 et utilisation
US6630584B1 (en) * 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
ATE437185T1 (de) 2005-03-25 2009-08-15 Univ Ramot Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon

Also Published As

Publication number Publication date
US8207309B2 (en) 2012-06-26
WO2006100681A2 (en) 2006-09-28
US8039594B2 (en) 2011-10-18
US20110262447A1 (en) 2011-10-27
JP2008533986A (ja) 2008-08-28
WO2006100681A3 (en) 2007-05-24
EP1863846B1 (de) 2009-07-22
US20100074908A1 (en) 2010-03-25
DE602006007967D1 (de) 2009-09-03
EP1863846A2 (de) 2007-12-12

Similar Documents

Publication Publication Date Title
ATE437185T1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
EA202192738A1 (ru) Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
CY1122210T1 (el) Ανθρωπινα αντισωματα anti-sod1
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DK2142570T3 (da) Anti-EpCam-antistof og anvendelser deraf
ATE461220T1 (de) Anti-egfr-antikörper
ATE497508T1 (de) Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
DK1706424T3 (da) FC-region varianter
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
EA200700847A1 (ru) Материалы, связывающие прионные белки, и способы их применения
RU2013119417A (ru) Антигенсвязывающие молекулы, которые связывают egfr, кодирующие их векторы и их применение
ATE414535T1 (de) Trägerproteine für impfstoffe
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
DE602004027992D1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
BRPI0607323A2 (pt) composições e uso de polipeptìdeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptìdeo
ATE537186T1 (de) P53-bindendes polypeptid
DK1864131T3 (da) Naturlig ligand af G protein koblet receptor RCC356 og anvendelser deraf
DE602006018424D1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
ATE470478T1 (de) An ovarialkrebs beteiligtes protein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties